(3aR,4S,5aR,9aR,9bR)-4-羟基-3,9-二亚甲基-5a-乙烯基-3a,4,5,6,9a,9b-六氢吡喃并[5,4-g]苯并呋喃-2,8-苯醌 | 18542-37-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 内酯类
• 中文名称: (3aR,4S,5aR,9aR,9bR)-4-羟基-3,9-二亚甲基-5a-乙烯基-3a,4,5,6,9a,9b-六氢吡喃并[5,4-g]苯并呋喃-2,8-苯醌
• 英文名称: dl-Vernolepin
• 英文别名: Vernolepin；(3aR,4S,5aR,9aR,9bR)-5a-ethenyl-4-hydroxy-3,9-dimethylidene-3a,4,5,6,9a,9b-hexahydrofuro[2,3-f]isochromene-2,8-dione
• CAS: 18542-37-5
• 化学式: C₁₅H₁₆O₅
• 分子量: 276.289
• InChiKey: IFYQXAXVZGMFNW-MVIRXUPPSA-N

物化性质

• 熔点：
  181-182°
• 比旋光度：
  D28 +72° (c = 1.04 in acetone)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  20
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  72.8
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• SYNTHESIS OF ISOTOPICALLY-LABELED FUNCTIONALIZED DIENES
  申请人：Martinez Rodolfo A.

  公开号：US20100317886A1

  公开（公告）日：2010-12-16

  All labeled carbons are derived ultimately from CO, as carbon-13 is separated from its lighter isotope by cyrogenic distillation of carbon monoxide (CO). Creation of stereospecific and site-specific compounds used for starting materials will address growing demands for labeled compounds, including isotopically-labeled functionalized dienes. Functionalized diene compounds can be used as precursors for the production of isotopically labeled pharmaceuticals, biomolecules, and natural products.

  所有标记的碳最终都来源于CO，因为碳-13是通过将一氧化碳（CO）进行低温分馏而与其较轻的同位素分离的。 制备用于起始材料的立体特异性和位点特异性化合物将满足对标记化合物的不断增长需求，包括同位素标记的官能化二烯烃。 官能化二烯烃化合物可用作生产同位素标记的药物、生物分子和天然产物的前体。
• [EN] A NEW CLASS OF HIGHLY APOPTOTIC ANTI-CANCER AGENTS<br/>[FR] NOUVELLE CLASSE D'AGENTS ANTICANCÉREUX HAUTEMENT APOPTOTIQUES
  申请人：CAGIR ALI

  公开号：WO2011099947A1

  公开（公告）日：2011-08-18

  This invention relates to a list of apoptosis-inducers consisting of 6-bicycloaryl substituted 5,6-dihydro-2H-pyran-2-one derivatives. According to the present invention, the apoptosis-inducers trigger cell death by expression of a list of apoptotic genes, so they can be useful for the treatment of cancers, or other autoimmune diseases suffering from the lack of apoptosis such as viral infections, diabetes type I, or encephalomyelitis.

  这项发明涉及一种由6-双环芳基取代的5,6-二氢-2H-吡喁-2-酮衍生物组成的凋亡诱导剂列表。根据本发明，这些凋亡诱导剂通过表达一系列凋亡基因来触发细胞死亡，因此它们可以用于治疗癌症或其他由于凋亡缺乏而受影响的自身免疫疾病，如病毒感染、1型糖尿病或脑脊髓炎。
• Reduction of hair growth
  申请人：THE GILLETTE COMPANY

  公开号：EP1352627A2

  公开（公告）日：2003-10-15

  A method of reducing hair growth in a mammal includes applying, to an area of skin from which reduced hair growth is desired, a dermatologically acceptable composition comprising an inhibitor of at least one enzyme active in the metabolic pathway for the conversion of glucose to acetyl-CoA.

  一种减少哺乳动物毛发生长的方法，包括向希望减少毛发生长的皮肤区域施用皮肤病学上可接受的组合物，该组合物包含至少一种在葡萄糖转化为乙酰-CoA 的代谢途径中具有活性的酶的抑制剂。
• Regulation of mammalian hair growth
  申请人：Oblong Erich John

  公开号：US20050003024A1

  公开（公告）日：2005-01-06

  The present invention relates to a topical skin care composition containing a safe and effective amount of a skin care active comprising agmatine, and its salt; a safe and effective amount of a first additional skin care active selected from the group consisting of BHT or BHA, hexamidine, cetyl pyridinium chloride, green tea catechins, phytosterols, ursolic acid, compounds derived from plant extracts, their salts and derivatives; and a dermatologically acceptable carrier for the agmatine composition. The present invention also relates to methods of using such agmatine compositions to regulate hair growth and the condition of mammalian skin. Said methods generally comprise the step of topically applying the composition to the skin of a mammal needing such treatment, a safe and effective amount of such compositions.

  本发明涉及一种局部皮肤护理组合物，该组合物含有安全有效量的皮肤护理活性物质，该活性物质包括阿matine 及其盐；安全有效量的第一种附加皮肤护理活性物质，该活性物质选自由 BHT 或 BHA、己脒、十六烷基氯化吡啶、绿茶儿茶素、植物甾醇、熊果酸、从植物提取物中提取的化合物、它们的盐和衍生物组成的组；以及皮肤病学上可接受的阿matine 组合物载体。本发明还涉及使用此类琼脂糖组合物调节毛发生长和哺乳动物皮肤状况的方法。所述方法一般包括将组合物局部施用到需要此类治疗的哺乳动物的皮肤上，施用安全有效量的此类组合物。
• Personal care compositions and methods regulating mammalian hair growth
  申请人：Oblong Erich John

  公开号：US20050255060A1

  公开（公告）日：2005-11-17

  Personal care compositions comprising at least one chronic skin care active selected from the group consisting of butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA), hexyl isobutyrate, menthyl anthranilate, methofuran, 3-butylidenepthalide, cetyl pyridinium chloride, green tea extract, catechins, phytosterols, ursolic acid, and plant extract compounds; at least one acute skin care active selected from the group consisting of particulate materials (including particles, pigments, and cross-linked silicone elastomers), alkane polyols, panthenol and pantothenic acid derivatives, and tanning actives; and a dermatologically acceptable carrier. The composition can also comprise the cationic thickener, Polyquaternium 37. The present invention also relates to methods of using such compositions to regulate hair growth and the condition of mammalian skin. Said methods generally comprise the step of topically applying the composition to the skin of a mammal needing such treatment, a safe and effective amount of such compositions.

  个人护理组合物，包含至少一种慢性皮肤护理活性物质，该活性物质选自由丁基化羟基甲苯（BHT）、丁基化羟基茴香醚（BHA）、异丁酸己酯、蒽酸薄荷酯、甲氧呋喃、3-丁基亚苯酞、氯化十六烷基吡啶鎓、绿茶提取物、儿茶素、植物甾醇、熊果酸和植物提取物化合物组成的组；至少一种急性皮肤护理活性物质，选自颗粒材料（包括微粒、颜料和交联硅弹性体）、烷烃多元醇、泛醇和泛酸衍生物以及鞣革活性物质组成的组；以及皮肤病学上可接受的载体。该组合物还可以包含阳离子增稠剂聚季铵盐 37。本发明还涉及使用此类组合物调节毛发生长和哺乳动物皮肤状况的方法。所述方法一般包括将组合物局部施用到需要此类治疗的哺乳动物的皮肤上，施用安全有效量的此类组合物。